ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
121.341,13
0,00%
S&P 500
5.464,62
0,00%
US Dollar vs BRL
5,4166
-0,60%
Bitcoin
61.067,21
-3,31%
Brent Oil
84,495
0,57%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Protagonist Therapeutics Inc (PTGX)

  7. Protagonist Therapeutics Inc (PTGX) Notícias

PTGX

Protagonist Therapeutics (PTGX)

Protagonist Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:PTGX
DataHoraFonteTítuloCódigoCompanhia
11/06/202417:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PTGXProtagonist Therapeutics Inc
07/06/202417:46Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:PTGXProtagonist Therapeutics Inc
07/05/202417:51Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PTGXProtagonist Therapeutics Inc
07/05/202417:29Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PTGXProtagonist Therapeutics Inc
16/04/202410:00GlobeNewswire Inc.Turnstone Biologics Appoints William Waddill to its Board of DirectorsNASDAQ:PTGXProtagonist Therapeutics Inc
14/02/202409:47Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:PTGXProtagonist Therapeutics Inc
18/12/202318:15Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:PTGXProtagonist Therapeutics Inc
11/08/202317:32Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:PTGXProtagonist Therapeutics Inc
12/05/202308:00PR Newswire (US)Protagonist Reports Positive Results from Phase 1 and Pre-clinical Studies of Oral Interleukin-23 Receptor Antagonist JNJ-2113NASDAQ:PTGXProtagonist Therapeutics Inc
11/05/202317:05PR Newswire (US)Protagonist Therapeutics to Participate in the JMP Securities Life Sciences ConferenceNASDAQ:PTGXProtagonist Therapeutics Inc
11/05/202311:17PR Newswire (US)Protagonist Therapeutics Announces Presentations at the 2023 Annual Congress of the European Hematology AssociationNASDAQ:PTGXProtagonist Therapeutics Inc
04/05/202317:39Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:PTGXProtagonist Therapeutics Inc
04/05/202317:22Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:PTGXProtagonist Therapeutics Inc
04/05/202317:05PR Newswire (US)Protagonist Reports First Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:PTGXProtagonist Therapeutics Inc
19/04/202317:29Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:PTGXProtagonist Therapeutics Inc
12/04/202318:17Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:PTGXProtagonist Therapeutics Inc
06/04/202307:02Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:PTGXProtagonist Therapeutics Inc
15/03/202318:02Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:PTGXProtagonist Therapeutics Inc
15/03/202317:52Edgar (US Regulatory)Annual Report (10-k)NASDAQ:PTGXProtagonist Therapeutics Inc
08/03/202304:05Dow Jones NewsProtagonist Therapeutics Sees Positive Topline Results in JNJ-2113 TrialNASDAQ:PTGXProtagonist Therapeutics Inc
07/03/202310:00PR Newswire (US)Protagonist Therapeutics Announces Positive Topline Results for Phase 2b FRONTIER 1 Clinical Trial of Oral IL-23 Receptor Antagonist JNJ-2113 (PN-235) in PsoriasisNASDAQ:PTGXProtagonist Therapeutics Inc
14/02/202318:25Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:PTGXProtagonist Therapeutics Inc
09/02/202313:45Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:PTGXProtagonist Therapeutics Inc
21/12/202218:05PR Newswire (US)Protagonist Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare ConferenceNASDAQ:PTGXProtagonist Therapeutics Inc
01/12/202209:05PR Newswire (US)Protagonist Therapeutics to Participate in the JMP Securities Hematology and Oncology SummitNASDAQ:PTGXProtagonist Therapeutics Inc
17/11/202220:21Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:PTGXProtagonist Therapeutics Inc
16/11/202218:05PR Newswire (US)Protagonist Therapeutics Reports Granting of Inducement AwardNASDAQ:PTGXProtagonist Therapeutics Inc
14/11/202201:10TipRanksAnalysts Are Bullish on Top Healthcare Stocks: Passage Bio (PASG), Privia Health Group (PRVA)NASDAQ:PTGXProtagonist Therapeutics Inc
09/11/202218:15TipRanksJMP Securities Remains a Buy on Protagonist Therapeutics (PTGX)NASDAQ:PTGXProtagonist Therapeutics Inc
08/11/202218:05PR Newswire (US)Protagonist Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateNASDAQ:PTGXProtagonist Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:PTGX

Seu Histórico Recente

LATK
GLMUSDT
Golem Network Token
TG
6SJA
SelectQuote
BIT
P20S59
NLBNPIT20S59 20241218 2000
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados